UPL NA v. Tide International: Federal Circuit Affirms PTAB on US7473685
UPL NA Inc. challenged Tide International's US7473685B2 — a patent covering a process for producing chemically stable, dust-free, soluble granules of phosphoroamidothioates — before the PTAB and then the Federal Circuit. The appellate court affirmed the Board's split decision: claims 1–4 unpatentable, claims 7–12 intact. The case resolved in 402 days.
Split claim outcome: half the patent falls, half survives Federal Circuit review
UPL NA Inc., as petitioner, initiated an inter partes review challenging US Patent 7,473,685 B2, owned by Tide International (USA), Inc. The patent covers a process for preparing chemically stable, dry-flow, low-compact, dust-free, soluble granules of phosphoroamidothioates — an agrochemical formulation technology. The PTAB issued a final written decision finding claims 1–4 unpatentable but declining to cancel claims 7–12. UPL appealed to the Court of Appeals for the Federal Circuit (Case No. 22-1514), filed 8 March 2022.
The Federal Circuit affirmed the Board's final written decision in full. The court found UPL's remaining arguments unpersuasive and concluded there was no reversible error in the Board's analysis. The recorded basis of termination is 'Unpatentable'; the appellate order states 'AFFIRMED.' Claims 1–4 of US7473685B2 are now cancelled as unpatentable; claims 7–12 remain in force and enforceable against third parties.
The 402-day duration is broadly consistent with Federal Circuit PTAB appeal timelines. The split outcome — four claims cancelled, six surviving — is commercially significant: Tide International retains enforceable coverage under claims 7–12, while the process steps captured in claims 1–4 are now in the public domain. The specific prior art references (Misselbrook, CN '588, JP '902, and Mayer) were central to the PTAB's unpatentability determinations; the Federal Circuit found no error in how the Board weighed them.
See Complete Case & Patent Analysis →Filing to Unpatentable in 402 days
402 days from filing to Federal Circuit affirmance — typical for a PTAB appeal at this court
US7473685B2 — Phosphoroamidothioate soluble granule preparation process
Any company developing or commercialising processes for phosphoroamidothioate soluble granule formulations should conduct a freedom-to-operate analysis specifically scoped to claims 7–12 of US7473685B2. Claims 1–4 are cancelled and no longer present a risk, but the surviving claims were upheld through both PTAB review and Federal Circuit appeal — they are not easily challenged again on the same prior art. R&D and regulatory teams evaluating granule formulation processes in this agrochemical class should treat this patent as an active enforcement risk.
Official order — verbatim text
The Federal Circuit's one-word affirmance — 'AFFIRMED' — confirms that the appellate panel found no reversible error under the substantial-evidence standard applicable to PTAB factual findings and de novo review of legal conclusions. The split outcome is now final at this court level: claims 1–4 of US7473685B2 are cancelled, while claims 7–12 survive with full enforceability. UPL's remaining arguments, described in the order as unpersuasive, leave the PTAB's prior art analysis undisturbed.
Federal Circuit affirms: what the ruling means for both parties
What 'AFFIRMED' means at the Federal Circuit
An affirmance by the Federal Circuit means the court found no reversible error in the PTAB's final written decision. The Board's conclusions — that claims 1–4 are unpatentable and claims 7–12 are not — stand as the final resolution. No further appeal within the federal court system is available at this level; the only remaining avenue would be a petition to the Supreme Court.
No reversible error foundTide International retains claims 7–12 of US7473685
The affirmance preserves Tide International's enforceability over claims 7–12 of US7473685B2. These claims survived the IPR challenge across all asserted prior art combinations, including Misselbrook combined with Mayer and CN '588. Tide can continue to assert these claims against competitors in the phosphoroamidothioate granule formulation space. The loss of claims 1–4, however, narrows the patent's coverage.
Claims 7–12 enforceableUPL secures cancellation of claims 1–4 but fails on 7–12
UPL NA succeeded in having claims 1–4 cancelled — meaning those process steps are no longer patent-protected. However, the Federal Circuit agreed with the PTAB that UPL did not meet its burden of proof by a preponderance of the evidence for claims 7–12. UPL's appellate arguments were found unpersuasive. The surviving claims may continue to present a freedom-to-operate risk for UPL and similarly situated manufacturers.
Claims 1–4 cancelled onlyNarrowed patent still poses risk in agrochemical granule formulation
The Federal Circuit's affirmance reinforces the PTAB's authority to issue split decisions and signals that surviving claims — here 7–12 — receive meaningful deference on appeal. For agrochemical formulators working with phosphoroamidothioate soluble granules, claims 7–12 of US7473685B2 remain a live enforcement risk. Competitors should conduct FTO analysis specifically against the surviving claim set, not the cancelled claims.
FTO review against claims 7–12Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | UPL NA INC. | Company | /Search in Eureka ↗ |
| Defendant | Tide International (USA), Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Joshua Goldberg | Attorney | Counsel for UPL NA INC.Search in Eureka ↗ |
| Plaintiff counsel | Maximilienne Giannelli | Attorney | Counsel for UPL NA INC.Search in Eureka ↗ |
| Plaintiff counsel | Parmanand K. Sharma | Attorney | Counsel for UPL NA INC.Search in Eureka ↗ |
| Plaintiff counsel | Rajeev Gupta | Attorney | Counsel for UPL NA INC.Search in Eureka ↗ |
| Plaintiff law firm | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | Law Firm | Representing UPL NA INC.Search in Eureka ↗ |
| Defendant counsel | Bailey K. Benedict | Attorney | Counsel for Tide International (USA), Inc.Search in Eureka ↗ |
| Defendant counsel | Laura E. Powell | Attorney | Counsel for Tide International (USA), Inc.Search in Eureka ↗ |
| Defendant counsel | Thad Charles Kodish | Attorney | Counsel for Tide International (USA), Inc.Search in Eureka ↗ |
| Defendant law firm | Fish & Richardson LLP | Law Firm | Representing Tide International (USA), Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in phosphoroamidothioate and agrochemical granule IP
Forward-looking patent and innovation intelligence for agrochemical formulation teams watching UPL NA, Tide International, and soluble granule process IP.
UPL NA's broader formulation patent activity
UPL NA's decision to pursue IPR on US7473685 — and then appeal to the Federal Circuit — suggests active monitoring of competitor formulation IP in the phosphoroamidothioate space. Tracking UPL's own filing activity in agrochemical granule and soluble formulation technologies may reveal how the company is building around surviving third-party patents in this category.
UPL NA formulation portfolioFiling trends in phosphoroamidothioate and organophosphate granule chemistry
Dust-free, soluble granule formats for organophosphate agrochemicals are a growing area of formulation innovation driven by handling safety and regulatory trends. Mapping patent filing activity in this domain — including process parameters, excipients, and granulation techniques — can surface white space and competitive crowding relevant to R&D investment decisions.
Granule formulation filing trendsTide International's IP position after claims 7–12 survive
Tide International's surviving claims 7–12 of US7473685B2 represent a reinforced IP position in phosphoroamidothioate granule process technology. Understanding the full scope of Tide International's patent portfolio — beyond this single patent — can help competitors and R&D teams assess the broader enforceability perimeter in this agrochemical formulation niche.
Tide International IP scopeProcess design-around opportunities near cancelled claims 1–4
The cancellation of claims 1–4 of US7473685B2 opens specific process steps in the phosphoroamidothioate granule preparation space to unrestricted use. R&D teams can now explore and potentially patent improvements on those cancelled process parameters without infringement risk, while designing around the surviving claims 7–12 to enter the market cleanly.
Design-around opportunitySimilar PTAB appeals on agrochemical formulation patents at the Federal Circuit
Explore Federal Circuit appeals affirming or reversing PTAB decisions on agrochemical and organophosphate formulation patents, including split-claim IPR outcomes.
What this case signals for the agrochemical formulation IP landscape
A split-claim affirmance at the Federal Circuit narrows but does not eliminate patent risk for phosphoroamidothioate granule producers.
Claims 7–12 of US7473685 remain enforceable — FTO is now urgent
With the Federal Circuit affirming the PTAB's split decision, any manufacturer of phosphoroamidothioate soluble granule processes must assess exposure under claims 7–12 specifically. The cancelled claims 1–4 are no longer a risk, but the surviving six claims carry full enforceability. Skipping FTO on the basis of partial cancellation would be an error.
Prior art combinations failed on claims 7–12 — prosecution record now matters
The PTAB and Federal Circuit both held that Misselbrook, CN '588, JP '902, and Mayer — alone and in combination — did not establish unpatentability for claims 7–12. Understanding exactly why those combinations failed is critical for any future IPR strategy or design-around analysis targeting Tide International's remaining claim scope.
UPL v Tide — key questions answered
The Federal Circuit affirmed the PTAB's final written decision. Claims 1–4 of US7473685B2 were held unpatentable based on prior art including Misselbrook, CN '588, and JP '902. Claims 7–12 survived all asserted prior art combinations. The court found UPL's remaining arguments unpersuasive and affirmed without modification.
Claims 1–4 of US7473685B2 were found unpatentable by the PTAB and that finding was affirmed by the Federal Circuit. Claims 7–12 were not shown to be unpatentable — they survived all prior art combinations asserted by UPL NA and remain in force and enforceable.
The PTAB and Federal Circuit considered prior art combinations including Misselbrook alone and combined with CN '588 and JP '902 (against claims 1–4), and Misselbrook combined with Mayer and CN '588, and Misselbrook combined with JP '902 and Mayer (against claims 7–12). The latter combinations were found insufficient to establish unpatentability for claims 7–12.
The cancelled claims 1–4 are no longer enforceable, so the specific process steps they covered are now open. However, claims 7–12 of US7473685B2 remain fully enforceable following the Federal Circuit affirmance. Any FTO analysis for phosphoroamidothioate soluble granule processes must be scoped to the surviving claims 7–12 specifically.
Having lost at the PTAB and on appeal at the Federal Circuit on the same prior art, UPL faces significant estoppel bars under 35 U.S.C. § 315(e) for grounds that were raised or reasonably could have been raised in the IPR. Further challenge at this appellate level is not available. The only remaining avenue is a petition to the Supreme Court, though that is a discretionary and rarely granted review.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.